Common variable immunodeficiency disorders (CVID) are the most frequent clinically relevant primary immunodefiency. Despite impaired humoral immunity, robust T cellular immune responses after SARS-CoV-2 infection and after COVID-19 and influenzavaccination were found. Quality and logevity of antibody responses to COVID-19 mRNA vaccination is significantly impaired in CVID patients.